Stock Ratings / Health Care / RMTI / forecast

RNAZ (47) NXTC (48) BCTX (41) CPHI (45) ⌘ Pro Terminal →

Rockwell Medical Inc. (RMTI) 12-Month Stock Forecast & Price Target Cone

$7.31 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Rockwell Medical Inc. (RMTI) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $29.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RMTI)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your RMTI Position Size: $10,000

Shares at $7.31: 1368.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $4.93

$6,744

$-3,256 (-32.6%)

12M Consensus BaseTarget $6.32

$8,646

$-1,354 (-13.5%)

12M Bull Case BreakoutTarget $13.55

$18,536

+$8,536 (+85.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$7	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$13	69%	B
JP MorganUS Large-Cap Research	SELL	$6	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RMTI)

✓Walkthrough of RMTI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RMTI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.93%📐 HORIZONTAL RANGE

2026-10-30O $6.94H $7.31L $6.71C $7.31VOL 39.5K

RES: $9.82SUP: $6.68SMA50: $7.91SMA200: $8.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RMTI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RMTI Butterfly Map → + Track RMTI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RMTI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RMTI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RMTI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RMTI)

Health Care Rank #971 of 1016 ⚔️ RNAZ vs RMTI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RMTI vs. RNAZ, NXTC, BCTX, CPHI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rockwell Medical Inc. (RMTI) ranks #971 by composite RQD confidence (28/100, grade E) and #806 by equity capitalization ($29.5M). Within this direct 5-issuer industry benchmark cohort, RMTI leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. NXTC currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with RMTI at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RMTI ACTIVE Rockwell Medical Inc.	E	28/100	—	16.9%	-10.6%	0.00%	$29.5M	Benchmark Subject
RNAZ TransCode Therapeutics Inc.	D	47/100	—	—	-35.0%	-0.57%	$29.3M	/rnaz-vs-rmti →
NXTC NextCure Inc.	D	48/100	—	—	-35.0%	+2.92%	$29.9M	/nxtc-vs-rmti →
BCTX BriaCell Therapeutics Corp.	D-	41/100	—	—	—	-5.43%	$28.9M	/bctx-vs-rmti →
CPHI China Pharma Holdings Inc.	D	45/100	—	-3.2%	-11.4%	+4.84%	$28.0M	/cphi-vs-rmti →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001041024

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rockwell Medical Inc. (RMTI) reported GAAP revenue of $69.3M (-31.8% vs. FY2024 revenue of $101.5M ) , GAAP net income of -$5.3M, operating cash flow of -$659.0K, and free cash flow of -$659.0K (-115.7% YoY). On the balance sheet, RMTI closed FY2025 with $57.1M in total assets against $8.8M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$69.3M	-$5.3M	-$659.0K	-$659.0K	$57.1M	$8.8M
FY2024 (FY)	2024-12-31	$101.5M	-$480.0K	$4.2M	$4.2M	$59.2M	$8.5M
FY2023 (FY)	2023-12-31	$0	-$8.4M	-$9.4M	-$9.4M	—	—

3. RMTI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RMTI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rockwell Medical Inc. (NASDAQ: RMTI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $7.31 (0.00% 1D, market cap $29.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RMTI ranks #971 in composite RQD confidence.

How does RMTI compare to RNAZ and NXTC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RMTI carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 16.9%, and ROIC of -10.6%. By comparison, RNAZ (TransCode Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $29.3M) and NXTC (NextCure Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $29.9M). Among the 5-stock peer group, RMTI leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RMTI?

Per RMTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001041024), Rockwell Medical Inc. generated $69.3M in revenue (-31.8% YoY), -$5.3M in net income, and -$659.0K in free cash flow against $57.1M in total assets and $8.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RMTI trading relative to its 50-day, 200-day, and 52-week technical levels?

RMTI last traded at $7.31 (0.00% on volume of 4,350 shares), positioning the stock -7.59% below its 50-day simple moving average ($7.91) and -11.29% below its 200-day simple moving average ($8.24). Across its 52-week range of $4.89 to $12.90, RMTI sits at the 30.2% percentile with a 14-day RSI of 41.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.40 to $8.22).

RMTI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is RMTI's 12-month stock price target?

Rockwell Medical Inc. (RMTI) carries a 12-month consensus base price target of $6.32 (-13.5% from $7.31), with a bull-case target of $13.55 and a bear-case floor of $4.93.